Save on Lorlatinib with Coupons, Discounts & Savings Programs

Lorlatinib is available as a 25 mg and 100 mg oral tablet.

Lorlatinib is a kinase inhibitor and is used to treat anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer that has spread to other parts of the body.

Lorlatinib is a targeted therapy anticancer medication that blocks a protein called anaplastic lymphoma kinase (ALK). The ALK protein is made by the ALK gene. This gene is something that everyone is born with. In people with ALK-positive NSCLC, this gene doesn’t work like it should. It ends up making abnormal proteins and causing cancer. LORBENA works to block the ALK protein, so cancer cells can’t grow and spread as well.

Lorlatinib is typically dosed at s 100 mg orally once daily.

Lorlatinib is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you. You should not use this medication if you are taking a strong CYP3A inducer.

Common side effects of Lorlatinib:

• High cholesterol and fat levels in blood
• Abnormal kidney labs
• Swelling in the eyelids, face, and hands and feet
• Abnormal liver protein labs
• Abnormal blood cell counts
• High blood sugar
• Nerve pain
• Weight gain
• Problems with memory and attention
• Trouble breathing
• Tiredness
• Abnormal pancreas labs
• Changes in mood
• Joint pain
• Diarrhea
• Changes in electrolyte levels

Serious side effects are rare with Lorlatinib. Contact your healthcare provider immediately if you experience any of the following.

• Suicidal thoughts and self-harm
• Severe lung problems: new or worsening breathing problems (e.g., coughing or trouble breathing) or fever
• Blocked heartbeat: feeling dizzy, faint, or a change in your heartbeat

The following medications may interact with Lorlatinib:

• CYP3A Inducers: Contraindicated with strong CYP3A inducers. Avoid concomitant use with moderate CYP3A inducers.
• CYP3A Inhibitors: Avoid concomitant use with strong CYP3A inhibitors; reduce Lorlatinib dose if concomitant use cannot be avoided
• CYP3A Substrates: Avoid concomitant use with CYP3A substrates where minimal concentration changes may lead to serious therapeutic failures

Various FDA-approved generic manufacturers

Lorlatinib can harm your unborn baby. Your healthcare provider will do a pregnancy test before you start treatment with Lorlatinib. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Lorlatinib. Females who are able to become pregnant should use effective non-hormonal birth control during treatment with Lorlatinib and for at least 6 months after the final dose of Lorlatinib. Birth control pills
(oral contraceptives) and other hormonal forms of birth control may not be effective if used during treatment with Lorlatinib. Talk to your healthcare provider about birth control choices that are right for you during this time.
Males who have female partners who are able to become pregnant should use effective birth control during treatment with Lorlatinib and for at least 3 months after the final dose of Lorlatinib.

• Lorbrena